Related Experiment Video

Updated: Apr 15, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.6K

[New agents for hypercholesterolemia]

Xavier Pintó1, María Carmen García Gómez2

  • 1Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Universidad de Barcelona, Barcelona, España.

Medicina Clinica
|March 31, 2015
PubMed

Insights

Many patients with high cardiovascular risk struggle to meet cholesterol goals due to medication issues. New therapies like PCSK9 inhibitors offer improved cholesterol lowering and hypercholesterolemia management.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Metabolic Diseases

Background:

  • A significant number of high cardiovascular risk patients fail to achieve therapeutic low-density lipoprotein cholesterol (LDL-C) goals.
  • Suboptimal medication use, poor patient tolerance, and limited efficacy of current drugs like statins and ezetimibe contribute to this challenge.
  • Novel therapeutic strategies are needed to effectively manage hypercholesterolemia and reduce cardiovascular risk.

Purpose of the Study:

  • To provide an overview of recently approved and investigational therapeutic agents for hypercholesterolemia.
  • To discuss the characteristics, efficacy, and safety profiles of emerging cholesterol-lowering medications.
  • To highlight advancements in managing patients with elevated cardiovascular risk and lipid disorders.

Main Methods:

  • Review of current literature on hypercholesterolemia treatments.
  • Analysis of clinical trial data for novel lipid-lowering agents.
  • Synthesis of information on the mechanisms of action and therapeutic potential of new drug classes.

Main Results:

  • Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors demonstrate significant LDL-C reduction and are a promising option for hypercholesterolemia management.
  • Agents targeting apolipoprotein B synthesis and microsomal transfer protein offer new avenues for severe hypercholesterolemia, including homozygous familial hypercholesterolemia.
  • Cholesteryl ester transfer protein (CETP) inhibitors show potent effects on HDL-C and LDL-C, but their cardiovascular benefits and safety require further investigation.

Conclusions:

  • Emerging therapies, particularly PCSK9 inhibitors, hold significant promise for optimizing cholesterol management in high-risk patients.
  • New drug classes are expanding treatment options for severe and refractory hypercholesterolemia.
  • Continued research is essential to fully establish the cardiovascular benefits and safety of novel agents like CETP inhibitors.

Keywords:
ArteriosclerosisFármacos hipolipidemiantesHypercholesterolemia treatmentHypolipidemic drugsLipid metabolismMetabolismo de los lípidosTratamiento de la hipercolesterolemia

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
2.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
605
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
621
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K